Adempas
Payments companies reported to CMS as associated with Adempas. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Adempas, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Adempas
These are the largest totals companies reported as associated with Adempas. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hyong Kim | La Jolla, CA | Internal Medicine | $111,663.62 |
| Paul Forfia | Philadelphia, PA | Cardiovascular Disease | $108,508.51 |
| Ashish Gupta | Phoenix, AZ | Cardiovascular Disease | $83,262.00 |
| Therese Sargent | Phoenix, AZ | Adult Health (Nurse Practitioner) | $69,957.82 |
| Alvaro Aranda Rodriguez | Guaynabo, PR | Pulmonary Disease | $68,406.34 |
| John Mcconnell | Louisville, KY | Pulmonary Disease | $60,250.71 |
| Hunter Champion | Columbus, GA | Cardiovascular Disease | $51,386.71 |
| Ronald Zolty | Omaha, NE | Cardiovascular Disease | $43,955.00 |
| Lana Melendres Groves | Albuquerque, NM | Pulmonary Disease | $43,295.18 |
| Anjali Vaidya | Philadelphia, PA | Advanced Heart Failure and Transplant Cardiology | $41,878.03 |
Prescribed Adempas?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.